BioWorld™ MedTech: Approval of aducanumab paves way for Alzheimer’s blood tests

Written By Joni Henderson

Developers of blood tests for the early diagnosis of Alzheimer’s disease (AD) are poised to see a spike in demand, following the FDA’s accelerated approval on Tuesday of Cambridge, Mass.-based Biogen Inc.’s AD drug treatment Aduhelm (aducanumab). The FDA’s decision paves the way for AD assays to move beyond aiding in drug development toward addressing ongoing issues with undiagnosed cases.

Joni Henderson
Previous

360Dx: C₂N Building Case for Alzheimer's Dx as Aducanumab Approval Promises to Impact Testing Space
Next

St. Louis Business Journal: C₂N Diagnostics has brought its Alzheimer’s blood test to market. Now it wants to expand in St. Louis and beyond.